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ised by questions 3 and 4 of the International Index of
Erectile Function (IIEF). Those questions were suitable for
our purposes because they describe the primary endpoints
of ED-treatment, as defined by the National Institutes of
Health. To test content validity and feasibility of valuing
ED-states, we explored the relation between the values and
background variables and analysed the factor structure of
the valuation space in patients and the general public.
RESULTS: The factor structure of the valuation space was
the same in patients and the general public and values
were not influenced by background variables, supporting
validity and feasibility of valuing disease specific out-
comes. According to the general public the mean improve-
ment on the IIEF equals an increase of utility from 0.76 to
0.87 on a scale of 0 (dead) to 1.0 (perfect health).
CONCLUSIONS: Treatment preferences can be measured
by attaching utility weights to disease specific outcomes.
The implication is that in cost-effectiveness analysis results
can be available quickly, even if only disease specific out-
comes are available from previous research. On basis of
the utility gain of 0.11, we expect the costs per QALY of
sildenafil to be about US $10,000.
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Early prostate cancer (PC) diagnosis as a result of screen-
ing may raise total survival index. Diagnostic level of PC
in screening population is 2.5%; diagnostic level of PC for
those, who asked independently for urological consulta-
tions is 1.5%. All these were the bases for starting the PC
screening program in the Oncology Science Center (OSC),
Russian Academy of Medical Science in 1996. Since the
beginning of the program 852 persons aged 50–80, who
previously were not diagnosed with PC, participated in
screening. Methods of diagnosis in present work were
manual rectal examination (MRE), transrectal ultrasound
(TRUS), and immunology examination—determination
of prostatic specific antigene (DPSA). Prostate punctional
biopsy with morphologic diagnostic was used to amplify
the results. We also evaluated the diagnostic parameters of
the methods used and estimated the cost-effectiveness of
diagnosis. In the first part of the research diagnostic costs
of screening a group were compared with that of the inde-
pendent patients of the OSC: 5000 people during 2-year
period. Of the latest 4700 persons were subjected to MRE,
1560 have passed TRUS, and 315 have passed DPSA. To-
tal diagnostic cost for screening group (2 rounds) was
equal to 1,120,655 RUB, while the same for the control
group of individual patients was equal to 3,331,400 RUB.
The difference of 2,210,745 RUB between the diagnostic
cost for the control group and the cost for screening group
was primarily due to the cost of MRE for the control
group. Thus, the first part of the research has shown that
the screening is more cost-effective for the group of the
adult aged 50–80. A decision tree model was figured out in
the second part of the research. It included data from the
literature, OSC’s clinical diagnostic results. Cost expecta-
tions were counted for each treatment strategy to estimate
economic effectiveness. This was done for each branch by
multiplying the cost and probability. Cost expectations for
treatment strategies for different PC stages were then com-
pared. The analysis of the decision tree mode has shown
that the average treatment cost in the screening group was
equal to 13,666 RUB per patient, taking into account the
probability of finding disease and various types of treating
including Taxotere. The same average for the control
group of independent patients was 17,082 RUB per pa-
tient. The significant difference in average costs in two
groups (3,416 RUB) is due to the larger weight of the pa-
tients with the later stages of the disease in control group,
who needed more expensive treatment courses.
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OBJECTIVE: Urinary incontinence (UI) is a condition
with high prevalence and the second most important rea-
son for admission to long-term care. The purpose of this
study is to use a micro-costing approach to estimate the in-
cremental costs of caring for the UI patients residing in
these facilities. The three levels of long-term care consid-
ered are skilled and intermediate nursing, and rest homes.
METHODS: Data collection took place in three phases.
Phase I data from a time and motion (TAM) study, is used
to develop a taxonomy of different care activities per-
formed for the incontinent patients and a corresponding
control group. In Phase II, a patient-level observational
study assessed the frequency of the caring activities ob-
served in Phase I. Caring activities of 130 patients (65 in
the case and control groups, respectively) from six long
term facilities are recorded at each shift for a week, pro-
ducing a total of 2,730 observations. In Phase III, investi-
gators distributed a facility-level survey to 49 facilities, in-
cluding all phase I and Phase II facilities. The survey
collected information on hourly wage for different types of
labor, unit costs of supplies, and laundry services. Phase III
survey data are combined with patient-level data from
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phase II in fixed effect regression models to estimate the ef-
fect of incontinence on caring costs for UI.
RESULTS: Compared with long-term care residents with-
out UI, those with occasional UI consumed $2.90 more
per shift on labor and supply costs, while those with fre-
quent UI consumed $5.76 more. Incremental laundry costs
per shift are $0.34. Our study suggests that, on average,
the increased cost of caring for a UI patient in a long term
care facility is $5,650 per year, after controlling for factors
such as patient demographics, insurance status, type of
long-term care, and shift.
CONCLUSIONS: Behavioral, pharmacological, and medi-
cal treatments that successfully control or alleviate UI condi-
tions may yield substantial savings in long-term care set-
tings.
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OBJECTIVES: To estimate the indirect costs of HIV and
AIDS for individuals in the United Kingdom based on uti-
lization of informal (non-medical) care and community
services; to compare these figures with direct costs; and to
demonstrate the multitude of budgets that are affected by
indirect costs.
METHODS: A prevalence-based model was used to deter-
mine the aggregate utilization by stage of progression (as-
ymptomatic HIV, symptomatic non-AIDS, AIDS). Sources
of data included SOPHID97 for prevalence figures; pub-
lished data by Petrou, et al. on service utilization and costs;
published figures from Lubeck and Fries and data from the
Positive Lives Employment Survey 1997 for disability; and
the UK Office of National Statistics Family Expenditure
Survey 1997–98 for disability and income data.
RESULTS: Annual indirect costs (converted to 1998 British
pounds) are £3,881.14 for asymptomatic HIV patients;
£7,865.17 for symptomatic non-AIDS patients; and
£21,695.13 for AIDS patients. These figures can be com-
pared to annual hospital direct cost figures published in
PharmacoEconomics in 1998, which were £2,391 for as-
ymptomatic HIV patients; £4,562 for symptomatic non-
AIDS patients; and £15,895 for AIDS patients. Thus, our
estimates of indirect costs are higher than the hospital direct
cost estimates for all three groups of HIV/AIDS patients.
CONCLUSIONS: The difference (in 1998 British pounds)
in annual indirect costs per patient between asymptomatic
and symptomatic non-AIDS patients is £3,984.03. The dif-
ference in annual indirect costs per patient between symp-
tomatic non-AIDS and AIDS patients is £13,829.96. These
differences demonstrate the potential for significant savings
if disease progression can be prevented or delayed. Focus on
indirect costs of HIV/AIDS demonstrates the complexity of
decision making when data is limited to direct medical costs
and raises an issue regarding who should have input into de-
cision making when multiple budgets are affected.
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OBJECTIVES: Lyme disease is an increasingly common
condition in the United States and temperate regions of
Europe and Asia. The reported cases have increased 25
fold since 1982. Recently two vaccines have been devel-
oped. Decisions about the cost effectiveness require consis-
tent cost estimates. The objective of this study is to identify
the costs of diagnosis, treatment, treatment failure, and
late diagnosis in a large HMO population located in an en-
demic area. Prior studies have not included the worried
well who are tested but do not receive treatment.
METHODS: This study is a matched retrospective cohort
study. 8,017 individuals tested or diagnosed with LD was
matched by age, gender, and zip code with a control popu-
lation. Standardized HMO and pharmacy costs were gath-
ered from the HMO claims system. Chronic disease status
was controlled using the Chronic Disease Score. Costs
were assessed for six weeks prior to first LD contact and
six weeks following first LD contact. Late-effect and treat-
ment failures were assessed separately for longer post-con-
tact windows. 
RESULTS: The mean 12 week per capita medical direct
expense for LD cases is 4.1 times higher than for the con-
trol group. The cost difference is highly significant (p 
0.001). Pharmacy expense is 1.77 times greater (p 
0.001).
CONCLUSIONS: The cost effectiveness of LD vaccines is
dependent on the identifying the cost of both treatment
and anxiety caused by the potential of tick-borne infec-
tion. The costs differences illustrated in this study empha-
size the importance of both true positives and the “wor-
ried-well” in assessing the total cost of LD to health
insurance sponsors.
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OBJECTIVES: The objective of this study was to measure
influenza-related hospitalization rates and cost in a man-
aged care population.
